What makes the drug unique is that it is inactive upon injection and activates in the presence of a localized site with excessive inflammation, according to the paper, published in the Journal of Immunology. A protein molecule keeps the drug inactive until it encounters inflammatory enzymes.
“This development is important because inhibition of inflammation in a non-specific manner reduces the natural ability to fight infections and is a common side effect of anti-inflammatory biologic therapeutic,” said Peleg Rider, PhD, researcher in BGU’s department of clinical biochemistry and pharmacology.
More articles on infection control:
Most healthcare workers improperly remove protective equipment
10 interesting developments in hand hygiene
Sleep apnea unrecognized in 87% of at-risk patients
